ED50 of Ciprofol Combined with Sufentanil for Fiber Bronchoscopy of Different Patient Populations with Pulmonary Tuberculosis

Abstract

Backgroud: Ciprofol is a promising sedative. At present, there were few clinical studies on the median effective dose (ED50) of ciprofol. The aim of this study was to compare the ED50 of ciprofol for fiberoptic bronchoscopy in pulmonary tuberculosis (TB) patients of different genders and ages. Methods：TB patients who underwent bronchoscopy examination and treatment at The Third People’s Hospital of Changzhou between May 2023 and June 2023 were selected, and divided into four groups according to stratified random method: Group N1 (non-elderly male patients), Group N2 (non-elderly female patients), Group N3 (elderly male patients), and Group N4 (elderly female patients). All patients received intravenous injection of 0.15 μg/kg sufentanil followed by injection of the test dose of ciprofol according to Dixon’s modified sequential method. Fiberoptic bronchoscopy was performed after the disappearance of the eyelash reflex. The initial dose of ciprofol in all four groups of TB patients was 0.4 mg/kg, and the ratio of adjacent doses was 1:1.1. The next patient received a 10% increase in the dose of ciprofol if the patient in the same group experienced positive reactions such as choking cough, frowning, and body movements during the endoscopy process. Otherwise, it was judged as a negative reaction, and the next patient received a 10% decrease in the dose of ciprofol. The transition from a positive reaction to a negative reaction was defined as a turning point, and the study of the group was terminated when seven turning points occurred. Hemodynamic parameters, oxygen saturation and adverse reactions were recorded at different time points in all groups. The Probit regression analysis method was used to calculate the ED50 of ciprofol in the four groups and compare between the groups. Results: The ED50 of ciprofol combined with 0.15 μg/kg sufentanil for bronchoscopy in the four groups were 0.465 mg/kg, 0.433 mg/kg, 0.420 mg/kg and 0.396 mg/kg, respectively. The ED50 of ciprofol in the Group N1 was significantly higher compared with the Group N2 and Group N3 (p<0.05). The ED50 of ciprofol in the Group N4 was significantly lower compared with the Group N2 and Group N3 (p<0.05). Conclusions: The ED50 of ciprofol used for fiber bronchoscopy in patients with TB of different genders and ages was different. Trial registration: The Chinese Clinical Trial Registry, ChiCTR2300071508, Registered on 17 May 2023.